Cancer Stem Cell News Volume 2.49 | Dec 11 2013

    Cancer Stem Cell News 2.49 December 11, 2013

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

    Therapeutic Activation of Macrophages and Microglia to Suppress Brain Tumor-Initiating Cells
    Investigators found that microglia derived from non-glioma human subjects markedly mitigated the sphere-forming capacity of glioma patient-derived brain tumor initiating cells in culture by inducing the expression of genes that control cell cycle arrest and differentiation. [Nat Neurosci] Abstract | Press Release
    Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture FREE Protocols

    PUBLICATIONS (Ranked by impact factor of the journal)
    Chemotherapy Activates Cancer-Associated Fibroblasts to Maintain Colorectal Cancer-Initiating Cells by IL-17A
    To interrogate the interplay between chemotherapy and cancer-initiating cells, researchers investigated cellular heterogeneity in human colorectal cancers. [J Exp Med] Abstract

    A Critical Role of CD29 and CD49f in Mediating Metastasis for Cancer-Initiating Cells Isolated from a Brca1-Associated Mouse Model of Breast Cancer
    The authors investigated metastatic potential of cancer stem cells (CSCs) isolated from mammary tumors of a Brca1-mutant mouse model. Their data indicated that CSCs, which are enriched in CD24+CD29+/CD49f+ cell population, displayed much higher migration ability than CD24CD29/CD49f cells in tissue culture and enhanced metastatic potential in allograft-nude mice. [Oncogene] Abstract

    Stearoyl-CoA Desaturase-1 Is a Key Factor for Lung Cancer-Initiating Cells
    Scientists showed both by RNA interference and through the use of a small molecule inhibitor that stearoyl-CoA desaturase is required for lung cancer spheroids propagation both in stable cell lines and in malignant pleural effusion-derived primary tumor cultures. [Cell Death Dis] Full Article

    Cancer Stem Cell Enrichment Marker CD98: A Prognostic Factor for Survival in Patients with Human Papillomavirus-Positive Oropharyngeal Cancer
    Scientists evaluated the association between the number of cancer stem cells and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma patients. [Eur J Cancer] Abstract

    Down-Modulation of SEL1L, an Unfolded Protein Response and Endoplasmic Reticulum Associated Degradation Protein, Sensitizes Glioma Stem Cells to the Cytotoxic Effect of Valproic Acid
    Researchers aimed to investigate the impact of proteostasis on glioma stem cells using valproic acid treatment combined with subversion of SEL1L, a crucial protein involved in homeostatic pathways, cancer aggressiveness and stem cell state maintenance. [J Chem Biol] Abstract

    Branched Chain Amino Acid Suppresses Hepatocellular Cancer Stem Cells through the Activation of Mammalian Target of Rapamycin
    Investigators examined the effects of branched chain amino acid on hepatocellular carcinoma cells expressing a hepatic cancer stem cell marker, EpCAM. [PLoS One] Full Article

    JNK Contributes to Temozolomide Resistance of Stem-Like Glioblastoma Cells via Regulation of MGMT Expression
    Researchers identified JNK as a novel player in the control of O6-methylguanine DNA methyltransferase (MGMT) expression and temozolomide resistance of glioblastoma cancer stem cells. [Int J Oncol] Abstract

    Role of the Hypoxia-Inducible Factor-1 Alpha Induced Autophagy in the Conversion of Non-Stem Pancreatic Cancer Cells into CD133+ Pancreatic Cancer Stem-Like Cells
    Investigators focused on whether non-stem pancreatic cancer cells can convert to stem-like cells and the role of hypoxia-inducible factor-1alpha and autophagy in modulating this conversation. [Cancer Cell Int]
    Abstract | Full Article

    Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells

    Fact or Fiction – Identifying the Elusive Multiple Myeloma Stem Cell
    Understanding the interaction of the Multiple Myeloma stem cell to the microenvironment and the mechanisms utilized by various stem cell-like populations to allow persistence and therapy-resistance can enable for better targeting of this cell population and potential eradication of the disease. [J Hematol Oncol]
    Abstract | Full Article

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    Hear from the leaders in the Cell Culture sector!

    Verastem Initiates Clinical Trial of Dual mTOR/PI3K Inhibitor
    Verastem, Inc. focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase I trial of VS-5584, a dual mTORC1/2 and PI3K inhibitor, in patients with advanced solid tumors or lymphoma. [Verastem, Inc.] Press Release

    Jacco van Rheenen Wins STEM CELLS Young Investigator Award
    Jacco van Rheenen, Ph.D., of the Hubrecht Institute in The Netherlands has been named the winner of the 8th Annual STEM CELLS Young Investigator Award for his investigation on how healthy and tumorigenic tissues are derived from and maintained by cancer stem cells, how tumor cells disseminate from primary tumors and how these disseminated tumor cells grow out in distant organs. [Vocus PRW Holdings, LLC] Press Release

    From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW Tumor Microenvironment and Signaling
    May 7-10, 2014
    Heidelberg, Germany

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

    Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

    Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

    Postdoctoral Position – Apoptosis, Cancer Biology (Washington State University)

    Postdoctoral Position – Skin Stem Cell and Cancer Biology (Karolinska Institutet)

    Postdoctoral Position – Nervous System Development and Tumor Biology (Karolinska Institutet)

    Postdoctoral Fellow – Breast Cancer Stem Cell Biology (University of Cincinnati)

    Research Fellowship – Cancer Biology (Harvard Medical School)

    Assistant Professor – Fundamental Mechanisms in Cancer Biology (Cornell University)

    Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

    Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

    Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email with your feedback.

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us